BES_Mark.jpg
KADMON ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of KDMN and Encourages Investors to Contact the Firm
09 sept. 2021 11h52 HE | Bragar Eagel & Squire
NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or...
BES_Mark.jpg
TRANSLATE BIO ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of TBIO and Encourages Investors to Contact the Firm
03 août 2021 11h37 HE | Bragar Eagel & Squire
NEW YORK, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors...
TBIO.jpg
Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development
03 août 2021 01h00 HE | Translate Bio, Inc.
-- Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas -- -- Fast tracks establishment of Sanofi’s recently announced mRNA Center...
TBIO.jpg
Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine
22 juin 2021 01h00 HE | Translate Bio, Inc.
-- Trial will evaluate potential of next generation of influenza vaccines with combined mRNA technology and flu vaccine development expertise -- -- Positive preclinical safety and immunogenicity data...
Rancho Santa Fe Bio.png
Rancho Santa Fe Bio, Inc. Enters into Worldwide Exclusive License Agreement with Sanofi for Ataciguat
17 juin 2021 05h00 HE | Rancho Santa Fe Bio
SAN DIEGO and PARIS, June 17, 2021 (GLOBE NEWSWIRE) -- Rancho Santa Fe Bio, Inc. (“RSF Bio” or the “Company”), a San Diego, California-based clinical-stage cardiovascular platform company, today...
logo-alt.png
Global Cancer CDK Inhibitor Market 2019-2029 - Pipeline Analysis is estimated to be US$ 16.1 billion by 2030 with a CAGR of 10.4% during the forecast period - by PMI
17 mars 2021 11h35 HE | PMI
Covina CA, March 17, 2021 (GLOBE NEWSWIRE) -- The Global Cancer CDK Inhibitor Market accounted for US$ 6.0 billion in 2019 and is estimated to be US$ 16.1 billion by 2029 and is anticipated to...
logo-alt.png
Global Rare Disease Market is estimated to be US$ 547.5 billion by 2030 with a CAGR of 13.1% during the forecast period - by PMI
24 févr. 2021 10h35 HE | PMI
Covina CA, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Global Rare Disease Market accounted for US$ 161.4 billion in 2020 and is estimated to be US$ 547.5 billion by 2030 and is anticipated to register a CAGR...
logo-alt.png
Global Pruritus Therapeutics Market – Analysis and Demand with Forecast Overview to 2029 - by PMI
20 janv. 2021 11h05 HE | PMI
Covina CA, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Growing worldwide prevalence of atopic dermatitis, allergic contact dermatitis, and urticaria is expected to drive market growth during the forecast...
logo-alt.png
Global Diabetes Drugs Market–Analysis and Demand with Forecast Overview to 2029 - by PMI
12 janv. 2021 10h05 HE | PMI
Covina, CA, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The significant growth in the market can be attributed to factors, such as the rising prevalence of diabetes and the increasing number of programs...
Nurix.png
Nurix Therapeutics Announces Expansion of its Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degradation Therapies
07 janv. 2021 07h00 HE | Nurix Therapeutics, Inc.
SAN FRANCISCO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the expansion of...